Effect of Acetyl-L-carnitine on Chronic Pancreatitis
TerminatedEarly phase 1NCT02538146
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
An open label pilot study will determine the effect of the amino acid nutritional supplement acetyl-L-carnitine (ALC) on pain, quality of life, well-being, and serum pro-inflammatory mediator and oxidative stress levels in volunteers with chronic pancreatitis. The ALC is given to all participants for 3 months, and assessments will occur at intake and after 3 months.
Study details
- Official title
- Acetyl-L-carnitine as Pain Therapy in Chronic Pancreatitis
- Conditions
- Interventions
- Dietary supplement: acetyl-L-carnitine 1000mg 2X per day for 3 months
- Sponsor
- Karin High
- Collaborators
- University of Kentucky
- Organization
- University of Kentucky
- Start date
- 2015-08
- Primary completion
- 2016-10
- Sex
- All
- Age range
- from 20 Years to 90 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Only patients with chronic pancreatitis are included. Exclusion Criteria: * Patients with pancreatic pseudocysts, abscesses, pseudoaneurysms, pancreatitic fistulas, pancreatic adenocarcinoma, * Females that are pregnant or lactating * Children are excluded. * Patients suffering from seizure or thyroid disorders are also excluded due to possible exaggeration of their symptoms from taking ALC according to manufacturer.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02538146